SPDYE9

Summary

SPDYE9 (speedy/RINGO cell cycle regulator family member E9, HGNC:45034) is a protein-coding gene on chromosome 7q11.23, encoding Speedy protein E9 (A0A494C191).

Enables acetylcholine receptor regulator activity.

Source: NCBI Gene 643909 — RefSeq curated summary.

At a glance

• MANE Select transcript: NM_001382554

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:45034
Approved symbol	SPDYE9
Name	speedy/RINGO cell cycle regulator family member E9
Location	7q11.23
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000262461
Ensembl biotype	protein_coding
Entrez	643909

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 1 protein_coding_CDS_not_defined, 1 protein_coding

ENST00000571071, ENST00000575125

RefSeq mRNA: 2 — MANE Select: NM_001382554 NM_001382554, NM_001422015

CCDS: CCDS94116

Canonical transcript exons

ENST00000575125 — 8 exons

Exon	Start	End
ENSE00002642934	73075972	73077453
ENSE00002669599	73085917	73086038
ENSE00003488592	73082888	73083106
ENSE00003603507	73081796	73081854
ENSE00003637163	73084109	73084691
ENSE00003843422	73078534	73078777
ENSE00003847105	73080483	73080568
ENSE00003849681	73078307	73078411

Expression profiles

Bgee: expression breadth ubiquitous, 125 present calls, max score 64.79.

Top tissues by expression

130 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
bone marrow cell	CL:0002092	64.79	silver quality
colonic epithelium	UBERON:0000397	61.24	silver quality
stromal cell of endometrium	CL:0002255	60.91	gold quality
skeletal muscle tissue	UBERON:0001134	59.60	gold quality
ventricular zone	UBERON:0003053	59.38	gold quality
testis	UBERON:0000473	59.07	gold quality
right testis	UBERON:0004534	58.98	gold quality
muscle tissue	UBERON:0002385	58.84	gold quality
left testis	UBERON:0004533	58.46	gold quality
ganglionic eminence	UBERON:0004023	56.72	gold quality
monocyte	CL:0000576	56.20	gold quality
cortical plate	UBERON:0005343	56.14	gold quality
leukocyte	CL:0000738	56.07	gold quality
granulocyte	CL:0000094	56.01	gold quality
hindlimb stylopod muscle	UBERON:0004252	55.10	silver quality
superior frontal gyrus	UBERON:0002661	53.87	gold quality
liver	UBERON:0002107	52.19	silver quality
prefrontal cortex	UBERON:0000451	52.09	gold quality
primary visual cortex	UBERON:0002436	51.38	gold quality
adrenal tissue	UBERON:0018303	50.28	gold quality
mucosa of transverse colon	UBERON:0004991	48.73	gold quality
mucosa of stomach	UBERON:0001199	48.53	gold quality
kidney	UBERON:0002113	48.50	gold quality
placenta	UBERON:0001987	48.47	gold quality
blood	UBERON:0000178	48.31	gold quality
endometrium	UBERON:0001295	48.21	gold quality
cortex of kidney	UBERON:0001225	48.17	gold quality
lymph node	UBERON:0000029	47.87	gold quality
smooth muscle tissue	UBERON:0001135	47.83	gold quality
frontal cortex	UBERON:0001870	47.57	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.32

Regulation

Is transcription factor: no

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
mus_musculus	Spdye4b	ENSMUSG00000029586
mus_musculus	Spdye4a	ENSMUSG00000039296
rattus_norvegicus	Spdye4	ENSRNOG00000058563

Paralogs (18): SPDYE1 (ENSG00000136206), SPDYE5 (ENSG00000170092), SPDYE2B (ENSG00000173678), SPDYE4 (ENSG00000183318), SPDYE12 (ENSG00000184616), SPDYE16 (ENSG00000185040), SPDYE17 (ENSG00000186645), SPDYE2 (ENSG00000205238), SPDYE18 (ENSG00000205482), SPDYE3 (ENSG00000214300), SPDYE21 (ENSG00000230358), SPDYE6 (ENSG00000260097), SPDYE8 (ENSG00000273520), SPDYE10 (ENSG00000274570), SPDYE11 (ENSG00000275976), SPDYE15 (ENSG00000286014), SPDYE13 (ENSG00000286038), SPDYE14 (ENSG00000286137)

Protein

Protein identifiers

Speedy protein E9 — A0A494C191 (reviewed: A0A494C191)

All UniProt accessions (1): A0A494C191

UniProt curated annotations — full annotation on UniProt →

Similarity. Belongs to the Speedy/Ringo family.

RefSeq proteins (2): NP_001369483, NP_001408944 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR020984	Speedy	Family
IPR057742	Speedy_E	Family

Pfam: PF11357

UniProt features (3 total): chain 1, region of interest 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-A0A494C191-F1	70.95	0.43

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 1 (showing top): chr7q11

GO Biological Process (1): positive regulation of cyclin-dependent protein serine/threonine kinase activity (GO:0045737)

GO Molecular Function (1): protein kinase binding (GO:0019901)

GO Cellular Component (0):

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of cyclin-dependent protein serine/threonine kinase activity	1
cyclin-dependent protein serine/threonine kinase activity	1
positive regulation of cell cycle	1
positive regulation of protein serine/threonine kinase activity	1
positive regulation of cyclin-dependent protein kinase activity	1
kinase binding	1

Protein interactions and networks

STRING

0 interactions, top by confidence (×1000):

IntAct

0 interactions, top by confidence:

ESM2 similar proteins: A0A0J9YY54, A0A494C086, A0A494C0Z2, A0A494C191, A6NHP3, A6NIY4, A6NJR5, A6NNV3, B4DH59, F6SZT2, P0C6Y7, P0CI01, P0DKJ7, P0DKJ8, P0DTA3, P0DUD1, P0DUD2, P0DUD3, P0DUD4, P0DUX0, P0DUX1, P0DV79, P79386, Q08AG5, Q13342, Q16666, Q3BBV2, Q495Y8, Q587J8, Q5JRC9, Q5QGU6, Q5RD14, Q5RKG3, Q63HK3, Q6ITT4, Q7TQI8, Q86T75, Q8IWY8, Q8N660, Q8NFV5

Diamond homologs: A0A494C086, A0A494C0Z2, A0A494C191, A6NHP3, A6NIY4, A6NJR5, A6NKU9, A6NLX3, A6NNV3, P0CI01, P0DTA3, P0DUD1, P0DUD2, P0DUD3, P0DUD4, P0DUX0, P0DUX1, P0DV79, Q495Y7, Q495Y8, Q5IBH6, Q5IBH7, Q5MJ68, Q5MJ70, Q8NFV5, Q8R496, Q9PU13, Q9YGL1

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

0 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	0
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

0 predictions. Top by Δscore:

AlphaMissense

1742 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:73082901:G:C	F112L	0.966
7:73082901:G:T	F112L	0.966
7:73082903:A:G	F112L	0.966
7:73080539:G:C	F146L	0.943
7:73080539:G:T	F146L	0.943
7:73080541:A:G	F146L	0.943
7:73078735:T:A	K179N	0.930
7:73078735:T:G	K179N	0.930
7:73081821:T:G	D128A	0.907
7:73078379:C:A	W257C	0.897
7:73078379:C:G	W257C	0.897
7:73081821:T:A	D128V	0.895
7:73080491:G:C	F162L	0.885
7:73080491:G:T	F162L	0.885
7:73080493:A:G	F162L	0.885
7:73080494:G:C	F161L	0.884
7:73080494:G:T	F161L	0.884
7:73080496:A:G	F161L	0.884
7:73078736:T:A	K179I	0.882
7:73078717:G:C	F185L	0.872
7:73078717:G:T	F185L	0.872
7:73078719:A:G	F185L	0.872
7:73080554:C:A	M141I	0.868
7:73080554:C:G	M141I	0.868
7:73080554:C:T	M141I	0.868
7:73081822:C:G	D128H	0.866
7:73081820:G:C	D128E	0.865
7:73081820:G:T	D128E	0.865
7:73080510:T:G	Y156S	0.861
7:73078381:A:G	W257R	0.859

dbSNP variants (sampled 300 via entrez): RS10241464 (7:73086377 A>G), RS1157161344 (7:73087477 C>T), RS1157208724 (7:73083737 T>C), RS1158102460 (7:73086178 T>C), RS1158169052 (7:73080478 C>T), RS1160655146 (7:73084062 C>G), RS1162269857 (7:73086397 A>G), RS1162522284 (7:73083289 C>T), RS1165844180 (7:73085733 TAGTC>T), RS1166250624 (7:73086449 CCTGT>C), RS1166570013 (7:73083424 A>C), RS1167373719 (7:73085781 G>A,T), RS1168041690 (7:73083653 A>C), RS1169721310 (7:73087162 A>C,G,T), RS1170534113 (7:73083445 G>C,T)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

2 total (human), top 2 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
lead acetate	affects cotreatment, increases expression	1
zinc protoporphyrin	affects cotreatment, increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.